A
Akoya Biosciences Inc
NASDAQ:AKYA
Akoya Biosciences Inc
NASDAQ:AKYA
Price:
1.29
USD
Market Closed
Market Cap:
$64.4m
Income Statement
Earnings Waterfall
Akoya Biosciences Inc
Akoya Biosciences Inc
Income Statement
Akoya Biosciences Inc
Akoya Biosciences Inc
Currency: USD
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Interest Expense |
3
|
3
|
3
|
3
|
3
|
3
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
9
|
10
|
10
|
10
|
10
|
|
| Revenue |
42
N/A
|
44
+3%
|
48
+10%
|
52
+7%
|
55
+6%
|
60
+9%
|
64
+8%
|
70
+8%
|
75
+7%
|
79
+6%
|
85
+7%
|
91
+7%
|
97
+6%
|
94
-3%
|
93
0%
|
87
-7%
|
82
-6%
|
80
-2%
|
|
| Gross Profit | |||||||||||||||||||
| Cost of Revenue |
(17)
|
(17)
|
(19)
|
(20)
|
(21)
|
(23)
|
(25)
|
(28)
|
(31)
|
(34)
|
(38)
|
(40)
|
(40)
|
(41)
|
(40)
|
(37)
|
(34)
|
(31)
|
|
| Gross Profit |
26
N/A
|
27
+3%
|
29
+11%
|
32
+8%
|
34
+7%
|
37
+8%
|
39
+6%
|
42
+6%
|
43
+4%
|
46
+5%
|
47
+4%
|
52
+9%
|
56
+9%
|
52
-7%
|
54
+2%
|
50
-7%
|
48
-4%
|
49
+3%
|
|
| Operating Income | |||||||||||||||||||
| Operating Expenses |
(38)
|
(43)
|
(48)
|
(57)
|
(74)
|
(84)
|
(99)
|
(107)
|
(110)
|
(114)
|
(118)
|
(118)
|
(114)
|
(110)
|
(107)
|
(95)
|
(89)
|
(86)
|
|
| Selling, General & Administrative |
(24)
|
(26)
|
(31)
|
(39)
|
(51)
|
(61)
|
(72)
|
(78)
|
(80)
|
(83)
|
(85)
|
(84)
|
(82)
|
(80)
|
(77)
|
(72)
|
(69)
|
(67)
|
|
| Research & Development |
(10)
|
(10)
|
(11)
|
(13)
|
(16)
|
(18)
|
(21)
|
(22)
|
(23)
|
(23)
|
(24)
|
(24)
|
(22)
|
(22)
|
(21)
|
(20)
|
(19)
|
(19)
|
|
| Depreciation & Amortization |
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(5)
|
(6)
|
(6)
|
(7)
|
(7)
|
(7)
|
(8)
|
(8)
|
(6)
|
(4)
|
(2)
|
(1)
|
(1)
|
|
| Other Operating Expenses |
(1)
|
(3)
|
(2)
|
(2)
|
(2)
|
1
|
(0)
|
(0)
|
0
|
0
|
(2)
|
(2)
|
(2)
|
(2)
|
(6)
|
(0)
|
1
|
1
|
|
| Operating Income |
(12)
N/A
|
(16)
-34%
|
(19)
-16%
|
(25)
-34%
|
(39)
-58%
|
(47)
-20%
|
(59)
-26%
|
(65)
-10%
|
(66)
-1%
|
(68)
-3%
|
(71)
-4%
|
(66)
+7%
|
(58)
+12%
|
(57)
+0%
|
(54)
+7%
|
(44)
+17%
|
(41)
+8%
|
(37)
+9%
|
|
| Pre-Tax Income | |||||||||||||||||||
| Interest Income Expense |
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
(4)
|
(5)
|
(5)
|
(5)
|
(6)
|
(6)
|
(7)
|
(8)
|
(8)
|
|
| Non-Reccuring Items |
(2)
|
(2)
|
1
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(4)
|
0
|
(6)
|
(6)
|
(2)
|
|
| Total Other Income |
(0)
|
(2)
|
(3)
|
(3)
|
(3)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
|
| Pre-Tax Income |
(17)
N/A
|
(23)
-36%
|
(24)
-5%
|
(31)
-31%
|
(43)
-39%
|
(51)
-19%
|
(63)
-23%
|
(69)
-10%
|
(71)
-2%
|
(73)
-3%
|
(76)
-5%
|
(71)
+6%
|
(63)
+11%
|
(68)
-7%
|
(60)
+11%
|
(58)
+4%
|
(55)
+5%
|
(47)
+14%
|
|
| Net Income | |||||||||||||||||||
| Tax Provision |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(17)
|
(23)
|
(24)
|
(31)
|
(43)
|
(51)
|
(63)
|
(69)
|
(71)
|
(73)
|
(76)
|
(71)
|
(63)
|
(68)
|
(60)
|
(58)
|
(55)
|
(48)
|
|
| Net Income (Common) |
(22)
N/A
|
(28)
-27%
|
(28)
-1%
|
(34)
-21%
|
(44)
-31%
|
(52)
-16%
|
(63)
-22%
|
(69)
-10%
|
(71)
-2%
|
(73)
-3%
|
(76)
-5%
|
(71)
+6%
|
(63)
+11%
|
(68)
-7%
|
(60)
+11%
|
(58)
+4%
|
(55)
+4%
|
(48)
+14%
|
|
| EPS (Diluted) |
-0.61
N/A
|
-1.19
-95%
|
-0.95
+20%
|
-0.91
+4%
|
-1.65
-81%
|
-1.37
+17%
|
-1.69
-23%
|
-1.82
-8%
|
-1.87
-3%
|
-1.9
-2%
|
-1.87
+2%
|
-1.45
+22%
|
-1.43
+1%
|
-1.38
+3%
|
-1.22
+12%
|
-1.17
+4%
|
-1.12
+4%
|
-0.96
+14%
|
|
Switch to:
Switch to:
See Also
Discover More
